Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ABBV 154

Drug Profile

ABBV 154

Alternative Names: ABBV-154

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AbbVie
  • Class Anti-inflammatories; Antirheumatics; Drug conjugates; Immunoconjugates; Steroids
  • Mechanism of Action Glucocorticoid receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Crohn's disease; Polymyalgia rheumatica
  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 09 Aug 2023 AbbVie terminates a phase II trial in Rheumatoid arthritis (Treatment-experienced) in USA, Ukraine, Turkey, Taiwan, Spain, Slovakia, Russia, Poland, Puerto Rico, New Zealand, Netherlands, South Korea, Japan, Italy, Israel, Hungary, Greece, Germany, Czech Republic, Canada and Australia (SC) due to business decision (NCT04888585)
  • 24 Jul 2023 Abbvie terminates a phase II (AIM-PMR) trial in Polymyalgia rheumatica (Treatment-experienced) in US, Australia, Austria, Canada, France, Germany, Hungary, Italy, Japan, South Korea, Netherlands, New Zealand, Poland, Spain, United Kingdom (SC) due to business decision (EudraCT2021-000648-23) (NCT04972968)
  • 20 Jul 2023 AbbVie terminates a Phase-II clinical trials in Crohn's disease in Australia, Austria, Belgium, Bulgaria, Canada, Czech Republic, France, Germany, Greece, Hungary, Israel, Italy, Japan, Netherlands, New Zealand, Poland, Portugal, Puerto Rico, Slovakia, South Korea, Spain, Taiwan, Turkey, United Kingdom, USA(SC) due to strategic considerations (NCT05068284)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top